P906: IXAZOMIB, DARATUMUMAB AND LOW DOSE DEXAMETHASONE IN FRAIL PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS OF THE MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY

P906: IXAZOMIB, DARATUMUMAB AND LOW DOSE DEXAMETHASONE IN FRAIL PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS OF THE MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY

Bibliographic Details
Main Authors:	K. Groen, M. Seefat, K. Nasserinejad, C. A. Stege, E. van der Spek, Y. M. Bilgin, A. Kentos, M. Sohne, R. J. van Kampen, I. Ludwig, N. Thielen, N. Durdu-Rayman, N. C. de Graauw, N. W. van de Donk, E. G. de Waal, M.-C. Vekemans, G. J. Timmers, M. van der Klift, S. Soechit, P. A. Geerts, M. H. Silbermann, M. Oosterveld, I. Nijhof, P. Sonneveld, S. K. Klein, M.-D. Levin, S. Zweegman
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000846496.51905.dd

Similar Items

P13 IXAZOMIB, DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
by: K. Groen, et al.
Published: (2023-05-01)

P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13
by: K. Groen, et al.
Published: (2022-06-01)

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
by: Kazimierz Groen, et al.
Published: (2023-09-01)

P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
by: Kaz Groen, et al.
Published: (2023-08-01)

P1105: FINAL RESULTS OF THE PHASE I/II HOVON124/ECWM-R2 STUDY INCLUDING 2-YEAR RITUXIMAB MAINTENANCE AFTER INDUCTION WITH IXAZOMIB, RITUXIMAB AND DEXAMETHASONE IN RELAPSED WALDENSTRÖM’S MACROGLOBULINEMIA
by: M.-A. Dimopoulos, et al.
Published: (2022-06-01)

P18 SKIN EXPRESSION OF P16INK4A, A BIOMARKER FOR CELLULAR SENESCENCE, DOES NOT PREDICT FRAILTY OR TREATMENT OUTCOME IN NEWLY DIAGNOSED MULTIPLE MYELOMA
by: F. Smits, et al.
Published: (2023-05-01)

P947: COMPARATIVE EFFECTIVENESS OF ORAL IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) AFTER INITIAL BORTEZOMIB (V)-BASED INDUCTION VS PARENTERAL V-BASED THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
by: R. M. Rifkin, et al.
Published: (2022-06-01)

PB2089: IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) ACCORDING TO AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSIS OF US MM-6
by: Saulius K. Girnius, et al.
Published: (2023-08-01)

P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY
by: J. Doorduijn, et al.
Published: (2022-06-01)

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trialResearch in context
by: Kaz Groen, et al.
Published: (2023-09-01)

Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial
by: Niek G. van der Maas, et al.
Published: (2024-03-01)

T‐cell pseudolymphoma secondary to ixazomib for multiple myeloma
by: M. Haq, et al.
Published: (2021-09-01)

B02 CARFILZOMIB AND LENALIDOMIDE-BASED THERAPY FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: RESULTS OF THE FINAL ANALYSIS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED 18-65 YEARS
by: N. van de Donk, et al.
Published: (2023-05-01)

P12 HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DOSE-ADJUSTED MELPHALAN-PREDNISONE-BORTEZOMIB (MPV)
by: M.R. Seefat, et al.
Published: (2023-05-01)

P366: BLINATUMOMAB ADDED TO PREPHASE AND CONSOLIDATION THERAPY IN NEWLY DIAGNOSED PRECURSOR B-ALL IN ADULTS. A PHASE II HOVON TRIAL
by: A. Rijneveld, et al.
Published: (2022-06-01)

P899: HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
by: Monique Minnema, et al.
Published: (2023-08-01)

B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS
by: P. Musto, et al.
Published: (2023-05-01)

906 De novo mutations in childhood-onset systemic lupus erythematosus
by: Tom Walsh, et al.
Published: (2022-12-01)

P53 REAL-WORLD TREATMENT SEQUENCES AND COSTS OF 96 PATIENTS WITH MULTIPLE MYELOMA FROM DIAGNOSIS TO DEATH
by: M.R. Seefat, et al.
Published: (2023-05-01)

New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib
by: Richardson PG, et al.
Published: (2017-08-01)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
by: Muz B, et al.
Published: (2016-01-01)

The added value of multi‐state modelling in a randomized controlled trial: The HOVON 102 study re‐analyzed
by: Katerina Bakunina, et al.
Published: (2022-02-01)

US patent no. 8,000,906 B2: Digital flowmeter
by: Henry, M, et al.
Published: (2011)

Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906)
by: Wing Lam, et al.
Published: (2018-11-01)

Sweet Syndrome Associated with Ixazomib
by: İrfan Yavaşoğlu, et al.
Published: (2021-08-01)

P1361: TREATMENT OF SEVERE STEROID-REFRACTORY ACUTE GVHD WITH MESENCHYMAL STROMAL CELLS: RESULTS OF THE PHASE III RANDOMIZED DOUBLE-BLIND MULTI-CENTER HOVON-113 TRIAL
by: L. Oosten, et al.
Published: (2022-06-01)

PB2023: UPDATE AND FOLLOW-UP OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WITH HIGH-RISK CYTOGENETIC (HRC).
by: M. I. Nuevo López, et al.
Published: (2022-06-01)

Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
by: Margot S.F. Roeten, et al.
Published: (2021-03-01)

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
by: Stefania Oliva, et al.
Published: (2021-06-01)

S249: SELECTIVE JAK2/IRAK1/ACVR1 INHIBITOR PACRITINIB BEFORE REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: FINAL ANALYSIS OF THE PHASE II HOVON-134 TRIAL
by: Ruben Van Dijck, et al.
Published: (2023-08-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

Ixazomib in the treatment of relapsed multiple myeloma
by: S. V. Semochkin
Published: (2018-07-01)

P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE
by: A. Schavgoulidze, et al.
Published: (2022-06-01)

Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study
by: Lee, HC, et al.
Published: (2024)

Impact of Comorbidities on Health-related Quality of Life in Nontransplant Eligible Patients With Newly Diagnosed Multiple Myeloma
by: M. Christine Bennink, et al.
Published: (2022-07-01)

P925: IMPACT OF PRIOR TREATMENT EXPOSURE ON THE EFFECTIVENESS OF IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE (THE INSURE STUDY)
by: H. C. Lee, et al.
Published: (2022-06-01)

Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups.
by: Kluin-Nelemans, H, et al.
Published: (2004)

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY
by: T. Facon, et al.
Published: (2022-06-01)

18.906 Algebraic Topology II, Spring 2006
by: Behrens, Mark
Published: (2020)

Directed evolution and immobilization of new lipase Lip 906
by: Dai Shuang, et al.
Published: (2021-01-01)